Dexcom

Dexcom

DXCM
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

DXCM · Stock Price

USD 60.91-23.76 (-28.06%)
Market Cap: $23.4B

Historical price data

Market Cap: $23.4BPipeline: 4 drugs (2 Phase 3)Patents: 20Founded: 1999Employees: 8,000-10,000HQ: San Diego, United States

Overview

Dexcom is a pioneering medical device company with a mission to empower people to take control of their health through innovative continuous glucose monitoring (CGM) technology. Founded in 1999, the company has achieved a dominant position in the diabetes care market with its best-in-class G7 systems and is now strategically expanding into the metabolic health space with its OTC Stelo biosensor. With a market cap of $24.44B, Dexcom's strategy leverages relentless product innovation, a robust payer coverage network, and a growing ecosystem of digital health partnerships to drive sustained growth.

DiabetesMetabolic Health

Technology Platform

Proprietary continuous glucose monitoring platform utilizing a glucose oxidase enzyme-based sensor, wireless transmitter, and a comprehensive digital ecosystem for real-time data display, analytics, and third-party integration.

Pipeline

4
4 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
Afrezza Inhalant ProductType 2 Diabetes Treated With InsulinApproved
verapamil 120mg tablet + placeboType1 DiabetesPhase 3
Sotagliflozin + PlaceboDiabetic NephropathiesPhase 3
Mini-glucagonType 1 DiabetesPre-clinical

Funding History

2
Total raised:$500M
Debt$500M
IPOUndisclosed

Company Timeline

1999Founded

Founded in San Diego, United States

2005IPO

Initial Public Offering

2019Debt

Debt: $500.0M